Hyderabad, Feb. 18 -- Kotak Alternate Asset Managers Limited ("Kotak Alts"), through its Kotak Life Sciences Fund I (KLSF-I), which invests in early to growth stage life sciences and healthcare businesses, has made an investment of INR 400 Mn in Zeroharm Sciences.
The investment marks a pivotal growth milestone for Zeroharm, providing capital to accelerate scale up, enhancing brand visibility, strengthening customer loyalty, and driving expansion into new markets, the company said in a release on Wednesday.
Ashish Ranjan, Director at Kotak Alts, said, "The Indian nutraceuticals market is supported by favourable macroeconomic, demand, and supply side drivers. It remains in the early stages of adoption and is poised for exponential growth. ...